Clay B. Siegall's most recent trade in Immunome Inc was a trade of 25,450 Common Stock done at an average price of $19.7 . Disclosure was reported to the exchange on March 27, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Immunome Inc | Clay B. Siegall | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 19.67 per share. | 27 Mar 2026 | 25,450 | 690,704 | - | 19.7 | 500,602 | Common Stock |
| Immunome Inc | Clay B. Siegall | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 21.15 per share. | 30 Dec 2025 | 4,729 | 665,254 | - | 21.1 | 100,018 | Common Stock |
| Immunome Inc | Clay B. Siegall | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 19 Dec 2025 | 200,000 | 660,525 | - | 0 | Common Stock | |
| Immunome Inc | Clay B. Siegall | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 20.48 per share. | 19 Dec 2025 | 7,278 | 860,525 | - | 20.5 | 149,053 | Common Stock |
| Immunome Inc | Clay B. Siegall | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 21.50 per share. | 18 Dec 2025 | 46,511 | 853,247 | - | 21.5 | 999,987 | Common Stock |
| Tourmaline Bio Inc | Clay B. Siegall | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 28 Oct 2025 | 20,000 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Tourmaline Bio Inc | Clay B. Siegall | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 28 Oct 2025 | 16,800 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Tourmaline Bio Inc | Clay B. Siegall | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 28 Oct 2025 | 15,000 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Shattuck Labs Inc | Clay B. Siegall | Director | Grant, award, or other acquisition of securities at price $ 0.87 per share. | 25 Aug 2025 | 128,054 | 128,054 | - | 0.9 | 111,112 | Common Stock |
| Shattuck Labs Inc | Clay B. Siegall | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Aug 2025 | 128,054 | 128,054 | - | - | Warrants (Right to Buy) | |
| Immunome Inc | Clay B. Siegall | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jul 2025 | 800,000 | 800,000 | - | - | Employee Stock Option (right to buy) | |
| Shattuck Labs Inc | Clay B. Siegall | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jul 2025 | 33,150 | 33,150 | - | - | Stock Option (Right to Buy) | |
| Tourmaline Bio Inc | Clay B. Siegall | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2025 | 16,800 | 16,800 | - | - | Stock Option (Right to Buy) | |
| Immunome Inc | Clay B. Siegall | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 7.29 per share. | 26 Mar 2025 | 137,100 | 806,736 | - | 7.3 | 999,459 | Common Stock |
| Immunome Inc | Clay B. Siegall | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 7.75 per share. | 31 Jan 2025 | 150,000 | 669,636 | - | 7.8 | 1,162,500 | Common Stock |
| Immunome Inc | Clay B. Siegall | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 9.54 per share. | 21 Nov 2024 | 66,057 | 485,693 | - | 9.5 | 630,263 | Common Stock |
| Immunome Inc | Clay B. Siegall | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 9.78 per share. | 21 Nov 2024 | 33,943 | 519,636 | - | 9.8 | 331,918 | Common Stock |
| Immunome Inc | Clay B. Siegall | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Aug 2024 | 800,000 | 800,000 | - | - | Stock option (right to buy) | |
| Shattuck Labs Inc | Clay B. Siegall | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2024 | 27,700 | 27,700 | - | - | Stock Option (Right to Buy) | |
| Tourmaline Bio Inc | Clay B. Siegall | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Immunome Inc | Clay B. Siegall | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 13.91 per share. | 20 May 2024 | 79,566 | 399,202 | - | 13.9 | 1,106,524 | Common Stock |
| Immunome Inc | Clay B. Siegall | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 13.78 per share. | 20 May 2024 | 20,434 | 419,636 | - | 13.8 | 281,548 | Common Stock |
| Shattuck Labs Inc | Clay B. Siegall | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2024 | 33,409 | 33,409 | - | - | Stock Option (Right to Buy) | |
| Seagen Inc | Clay B. Siegall | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 125.39 per share. | 12 May 2022 | 10,593 | 666,060 (0%) | 0% | 125.4 | 1,328,256 | Common Stock |
| Seagen Inc | Clay B. Siegall | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 May 2022 | 10,593 | 51,129 | - | - | Non-Qualified Stock Option (right to buy) | |
| Seagen Inc | Clay B. Siegall | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 26.10 per share. | 12 May 2022 | 10,593 | 676,653 (0%) | 0% | 26.1 | 276,477 | Common Stock |
| Seagen Inc | Clay B. Siegall | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 26.10 per share. | 12 May 2022 | 6,450 | 672,510 (0%) | 0% | 26.1 | 168,345 | Common Stock |
| Seagen Inc | Clay B. Siegall | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 May 2022 | 6,450 | 61,722 | - | - | Non-Qualified Stock Option (right to buy) | |
| Seagen Inc | Clay B. Siegall | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 126.18 per share. | 12 May 2022 | 6,450 | 666,060 (0%) | 0% | 126.2 | 813,861 | Common Stock |
| Nurix Therapeutics Inc | Clay B. Siegall | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2022 | 17,500 | 17,500 | - | - | Director Stock Option (right to buy) | |
| Seagen Inc | Clay B. Siegall | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Mar 2022 | 6,643 | 89,215 | - | - | Non-Qualified Stock Option (right to buy) | |
| Seagen Inc | Clay B. Siegall | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 134.74 per share. | 07 Mar 2022 | 6,643 | 667,945 (0%) | 0% | 134.7 | 895,078 | Common Stock |
| Seagen Inc | Clay B. Siegall | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 26.10 per share. | 07 Mar 2022 | 6,643 | 674,588 (0%) | 0% | 26.1 | 173,382 | Common Stock |
| Seagen Inc | Clay B. Siegall | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Mar 2022 | 4,000 | 85,215 | - | - | Non-Qualified Stock Option (right to buy) | |
| Seagen Inc | Clay B. Siegall | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 135.62 per share. | 07 Mar 2022 | 4,000 | 667,945 (0%) | 0% | 135.6 | 542,480 | Common Stock |
| Seagen Inc | Clay B. Siegall | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 26.10 per share. | 07 Mar 2022 | 4,000 | 671,945 (0%) | 0% | 26.1 | 104,400 | Common Stock |
| Seagen Inc | Clay B. Siegall | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Mar 2022 | 3,900 | 98,258 | - | - | Non-Qualified Stock Option (right to buy) | |
| Seagen Inc | Clay B. Siegall | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 132.72 per share. | 07 Mar 2022 | 3,900 | 667,945 (0%) | 0% | 132.7 | 517,608 | Common Stock |
| Seagen Inc | Clay B. Siegall | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 26.10 per share. | 07 Mar 2022 | 3,900 | 671,845 (0%) | 0% | 26.1 | 101,790 | Common Stock |
| Seagen Inc | Clay B. Siegall | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Mar 2022 | 2,400 | 95,858 | - | - | Non-Qualified Stock Option (right to buy) | |
| Seagen Inc | Clay B. Siegall | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 133.69 per share. | 07 Mar 2022 | 2,400 | 667,945 (0%) | 0% | 133.7 | 320,856 | Common Stock |
| Seagen Inc | Clay B. Siegall | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 26.10 per share. | 07 Mar 2022 | 2,400 | 670,345 (0%) | 0% | 26.1 | 62,640 | Common Stock |
| Seagen Inc | Clay B. Siegall | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 136.33 per share. | 07 Mar 2022 | 100 | 667,945 (0%) | 0% | 136.3 | 13,633 | Common Stock |
| Seagen Inc | Clay B. Siegall | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Mar 2022 | 100 | 102,158 | - | - | Non-Qualified Stock Option (right to buy) | |
| Seagen Inc | Clay B. Siegall | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 26.10 per share. | 07 Mar 2022 | 100 | 668,045 (0%) | 0% | 26.1 | 2,610 | Common Stock |
| Seagen Inc | Clay B. Siegall | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 139.96 per share. | 07 Feb 2022 | 8,985 | 667,945 (0%) | 0% | 140.0 | 1,257,541 | Common Stock |
| Seagen Inc | Clay B. Siegall | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 26.10 per share. | 07 Feb 2022 | 8,985 | 676,930 (0%) | 0% | 26.1 | 234,509 | Common Stock |
| Seagen Inc | Clay B. Siegall | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Feb 2022 | 8,985 | 106,642 | - | - | Non-Qualified Stock Option (right to buy) | |
| Seagen Inc | Clay B. Siegall | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 26.10 per share. | 07 Feb 2022 | 4,084 | 672,029 (0%) | 0% | 26.1 | 106,592 | Common Stock |
| Seagen Inc | Clay B. Siegall | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Feb 2022 | 4,084 | 102,558 | - | - | Non-Qualified Stock Option (right to buy) | |
| Seagen Inc | Clay B. Siegall | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 140.83 per share. | 07 Feb 2022 | 4,084 | 667,945 (0%) | 0% | 140.8 | 575,150 | Common Stock |
| Seagen Inc | Clay B. Siegall | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 138.97 per share. | 07 Feb 2022 | 3,574 | 667,945 (0%) | 0% | 139.0 | 496,679 | Common Stock |
| Seagen Inc | Clay B. Siegall | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 26.10 per share. | 07 Feb 2022 | 3,574 | 671,519 (0%) | 0% | 26.1 | 93,281 | Common Stock |
| Seagen Inc | Clay B. Siegall | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Feb 2022 | 3,574 | 115,627 | - | - | Non-Qualified Stock Option (right to buy) | |
| Seagen Inc | Clay B. Siegall | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Feb 2022 | 300 | 102,258 | - | - | Non-Qualified Stock Option (right to buy) | |
| Seagen Inc | Clay B. Siegall | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 141.56 per share. | 07 Feb 2022 | 300 | 667,945 (0%) | 0% | 141.6 | 42,468 | Common Stock |
| Seagen Inc | Clay B. Siegall | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 26.10 per share. | 07 Feb 2022 | 300 | 668,245 (0%) | 0% | 26.1 | 7,830 | Common Stock |
| Seagen Inc | Clay B. Siegall | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 137.29 per share. | 07 Feb 2022 | 100 | 667,945 (0%) | 0% | 137.3 | 13,729 | Common Stock |
| Seagen Inc | Clay B. Siegall | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 26.10 per share. | 07 Feb 2022 | 100 | 668,045 (0%) | 0% | 26.1 | 2,610 | Common Stock |
| Seagen Inc | Clay B. Siegall | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Feb 2022 | 100 | 119,201 | - | - | Non-Qualified Stock Option (right to buy) | |
| Seagen Inc | Clay B. Siegall | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 143.91 per share. | 07 Jan 2022 | 8,163 | 667,945 (0%) | 0% | 143.9 | 1,174,737 | Common Stock |
| Seagen Inc | Clay B. Siegall | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 26.10 per share. | 07 Jan 2022 | 8,163 | 676,108 (0%) | 0% | 26.1 | 213,054 | Common Stock |
| Seagen Inc | Clay B. Siegall | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jan 2022 | 8,163 | 119,301 | - | - | Non-Qualified Stock Option (right to buy) | |
| Seagen Inc | Clay B. Siegall | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 144.82 per share. | 07 Jan 2022 | 4,560 | 667,945 (0%) | 0% | 144.8 | 660,379 | Common Stock |
| Seagen Inc | Clay B. Siegall | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 26.10 per share. | 07 Jan 2022 | 4,560 | 672,505 (0%) | 0% | 26.1 | 119,016 | Common Stock |
| Seagen Inc | Clay B. Siegall | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jan 2022 | 4,560 | 127,464 | - | - | Non-Qualified Stock Option (right to buy) | |
| Seagen Inc | Clay B. Siegall | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jan 2022 | 3,221 | 132,024 | - | - | Non-Qualified Stock Option (right to buy) | |
| Seagen Inc | Clay B. Siegall | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 145.84 per share. | 07 Jan 2022 | 3,221 | 667,945 (0%) | 0% | 145.8 | 469,751 | Common Stock |
| Seagen Inc | Clay B. Siegall | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 26.10 per share. | 07 Jan 2022 | 3,221 | 671,166 (0%) | 0% | 26.1 | 84,068 | Common Stock |
| Seagen Inc | Clay B. Siegall | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jan 2022 | 1,100 | 135,245 | - | - | Non-Qualified Stock Option (right to buy) | |
| Seagen Inc | Clay B. Siegall | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 26.10 per share. | 07 Jan 2022 | 1,100 | 669,045 (0%) | 0% | 26.1 | 28,710 | Common Stock |
| Seagen Inc | Clay B. Siegall | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 147.16 per share. | 07 Jan 2022 | 1,100 | 667,945 (0%) | 0% | 147.2 | 161,876 | Common Stock |
| Seagen Inc | Clay B. Siegall | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 149.85 per share. | 20 Dec 2021 | 1,227 | 667,945 (0%) | 0% | 149.9 | 183,866 | Common Stock |
| Seagen Inc | Clay B. Siegall | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Dec 2021 | 14,691 | 153,215 | - | - | Non-Qualified Stock Option (right to buy) | |
| Seagen Inc | Clay B. Siegall | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 148.27 per share. | 07 Dec 2021 | 14,691 | 669,172 (0%) | 0% | 148.3 | 2,178,235 | Common Stock |
| Seagen Inc | Clay B. Siegall | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 26.10 per share. | 07 Dec 2021 | 14,691 | 683,863 (0%) | 0% | 26.1 | 383,435 | Common Stock |
| Seagen Inc | Clay B. Siegall | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Dec 2021 | 12,238 | 167,906 | - | - | Non-Qualified Stock Option (right to buy) | |
| Seagen Inc | Clay B. Siegall | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 147.83 per share. | 07 Dec 2021 | 12,238 | 669,172 (0%) | 0% | 147.8 | 1,809,144 | Common Stock |
| Seagen Inc | Clay B. Siegall | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 26.10 per share. | 07 Dec 2021 | 12,238 | 681,410 (0%) | 0% | 26.1 | 319,412 | Common Stock |
| Seagen Inc | Clay B. Siegall | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Dec 2021 | 11,522 | 141,693 | - | - | Non-Qualified Stock Option (right to buy) | |
| Seagen Inc | Clay B. Siegall | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 149.56 per share. | 07 Dec 2021 | 11,522 | 669,172 (0%) | 0% | 149.6 | 1,723,230 | Common Stock |
| Seagen Inc | Clay B. Siegall | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 26.10 per share. | 07 Dec 2021 | 11,522 | 680,694 (0%) | 0% | 26.1 | 300,724 | Common Stock |
| Seagen Inc | Clay B. Siegall | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Dec 2021 | 5,348 | 136,345 | - | - | Non-Qualified Stock Option (right to buy) | |
| Seagen Inc | Clay B. Siegall | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 150.38 per share. | 07 Dec 2021 | 5,348 | 669,172 (0%) | 0% | 150.4 | 804,232 | Common Stock |
| Seagen Inc | Clay B. Siegall | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 26.10 per share. | 07 Dec 2021 | 5,348 | 674,520 (0%) | 0% | 26.1 | 139,583 | Common Stock |
| Seagen Inc | Clay B. Siegall | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Dec 2021 | 1,650 | 180,144 | - | - | Non-Qualified Stock Option (right to buy) | |
| Seagen Inc | Clay B. Siegall | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 146.54 per share. | 07 Dec 2021 | 1,650 | 669,172 (0%) | 0% | 146.5 | 241,791 | Common Stock |
| Seagen Inc | Clay B. Siegall | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 26.10 per share. | 07 Dec 2021 | 1,650 | 670,822 (0%) | 0% | 26.1 | 43,065 | Common Stock |
| Seagen Inc | Clay B. Siegall | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 166.22 per share. | 23 Sep 2021 | 714 | 669,172 (0%) | 0% | 166.2 | 118,681 | Common Stock |
| Seagen Inc | Clay B. Siegall | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 167.52 per share. | 31 Aug 2021 | 9,564 | 673,245 (0%) | 0% | 167.5 | 1,602,118 | Common Stock |
| Seagen Inc | Clay B. Siegall | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 167.52 per share. | 31 Aug 2021 | 4,787 | 668,458 (0%) | 0% | 167.5 | 801,897 | Common Stock |
| Seagen Inc | Clay B. Siegall | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 166.79 per share. | 27 Aug 2021 | 32,800 | 696,147 (0%) | 0% | 166.8 | 5,470,712 | Common Stock |
| Seagen Inc | Clay B. Siegall | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 168.86 per share. | 27 Aug 2021 | 12,213 | 731,028 (0%) | 0% | 168.9 | 2,062,287 | Common Stock |
| Seagen Inc | Clay B. Siegall | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 170.27 per share. | 27 Aug 2021 | 8,662 | 682,809 (0%) | 0% | 170.3 | 1,474,879 | Common Stock |
| Seagen Inc | Clay B. Siegall | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 167.62 per share. | 27 Aug 2021 | 2,906 | 693,241 (0%) | 0% | 167.6 | 487,104 | Common Stock |
| Seagen Inc | Clay B. Siegall | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 170.16 per share. | 27 Aug 2021 | 2,081 | 728,947 (0%) | 0% | 170.2 | 354,103 | Common Stock |
| Seagen Inc | Clay B. Siegall | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 168.19 per share. | 27 Aug 2021 | 1,770 | 691,471 (0%) | 0% | 168.2 | 297,696 | Common Stock |
| Seagen Inc | Clay B. Siegall | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Aug 2021 | 74,549 | 74,549 | - | - | Non-Qualified Stock Option (right to buy) | |
| Seagen Inc | Clay B. Siegall | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Aug 2021 | 30,821 | 743,241 (0%) | 0% | 0 | Common Stock | |
| Seagen Inc | Clay B. Siegall | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 154.55 per share. | 16 Aug 2021 | 2,789 | 712,420 (0%) | 0% | 154.6 | 431,051 | Common Stock |
| Seagen Inc | Clay B. Siegall | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Aug 2021 | 642 | 642 | - | - | Incentive Stock Option (right to buy) |